Summary
Monoclonal antibodies have become a mainstay of therapy in common immune-mediated diseases (IMID) including Crohn’s disease (CD), rheumatoid arthritis (RA), and psoriasis (PsO). Current therapeutics include antibodies (“biologicals”) targeting inflammatory proteins such as Tumor Necrosis Factor (adalimumab), leukocyte trafficking (vedolizumab), or IL-12/IL-23 (ustekinumab). At present however, it cannot be predicted which biological will be effective in an individual patient, with only
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101095449 |
| Start date: | 01-01-2023 |
| End date: | 31-12-2026 |
| Total budget - Public funding: | 9 376 995,25 Euro - 9 376 995,00 Euro |
Cordis data
Original description
Monoclonal antibodies have become a mainstay of therapy in common immune-mediated diseases (IMID) including Crohn’s disease (CD), rheumatoid arthritis (RA), and psoriasis (PsO). Current therapeutics include antibodies (“biologicals”) targeting inflammatory proteins such as Tumor Necrosis Factor (adalimumab), leukocyte trafficking (vedolizumab), or IL-12/IL-23 (ustekinumab). At present however, it cannot be predicted which biological will be effective in an individual patient, with onlyStatus
SIGNEDCall topic
HORIZON-HLTH-2022-TOOL-11-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Search
Organisations
-
| STICHTING VUMC (Coördinator)
-
| ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (Coördinator)
-
| ALIMENTIV BV
-
| ASPHALION SL
-
| BELGIAN IBD RESEARCH AND DEVELOPMENT
-
| DESCIN BV
-
| DIAGENODE
-
| EUROPEAN FEDERATION OF CROHN'S AND ULCERATIVE COLITIS ASSOCIATIONS
-
| GENOME DIAGNOSTICS B.V
-
| Ghent University
-
| HORAIZON TECHNOLOGY B.V.
-
| INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES
-
| KING'S COLLEGE LONDON
-
| STICHTING VU
-
| SZEGEDI TUDOMANYEGYETEM